Takumi Ito

Years Active: 2020-2024
Publications (10 Years): 8

Tokyo Medical University

Tokyo Institute of Technology (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Tokyo Medical University Oct 01 2013

Japan

Associate Professor :: Department of Nanoparticle Translational Research

Education History

Tokyo Institute of Technology

Japan

PHD :: Graduate School of Bioscience and Biotechnology

Publications

Takumi Ito
Protein degraders - from thalidomide to new PROTACs. Journal of biochemistry 175 (5) (2024)
Takumi Ito
Protein degraders - from thalidomide to new PROTACs. Journal of biochemistry 175 (5) (2024)
Takumi Ito
Protein degraders - from thalidomide to new PROTACs. Journal of biochemistry 175 (5) (2024)
Takumi Ito
Protein degraders -from thalidomide to new PROTACs. Journal of biochemistry (2023)
Junichi Yamamoto, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa
Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders. Chemical Society reviews 51 (15) (2022)
Nobuyuki Shimizu, Tomoko Okumura, Junichi Yamamoto, Yuki Yamaguchi, Hiroshi Handa, Takumi Ito
PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates. Communications biology 4 (1) (2021)
Shumpei Tateno, Midori Iida, Satoshi Fujii, Tetsufumi Suwa, Miki Katayama, Haruka Tokuyama, Junichi Yamamoto, Takumi Ito, Satoshi Sakamato, Hiroshi Handa, Yuki Yamaguchi
Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide. Scientific reports 10 (1) (2020)
Junichi Yamamoto, Tetsufumi Suwa, Yuki Murase, Shumpei Tateno, Hirotaka Mizutome, Tomoko Okumura, Nobuyuki Shimizu, Tsutomu Kishi, Shuji Momose, Masahiro Kizaki, Takumi Ito, Yuki Yamaguchi, Hiroshi Handa
ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells. Nature chemical biology 16 (11) (2020)

Takumi Ito.css-eqlu8i{font-size:small;padding-left:4px;}